Shared decision making for HER2-negative metastatic breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how doctors and patients make decisions together about treatment for HER2-negative metastatic breast cancer. By joining, you'll help improve how treatment choices are discussed, and you may feel more involved in your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic breast cancer (cancer that has spread beyond the breast).
- Your cancer is HER2-negative (a type that doesn't have extra HER2 protein).
- You are starting or currently receiving your first treatment for metastatic breast cancer.
- You are at least 18 years old.
- You agree to take part and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
This trial tests a group-based lifestyle program for women with HR+/HER2- metastatic breast cancer. The program helps you improve diet, increase physical activity, and learn mind-body practices in a supportive group setting.
This trial tests a new combination of two targeted medicines for people with a certain type of advanced breast cancer that has grown despite hormone therapy. The medicines may help shrink tumors and slow the cancer's growth.
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
This study tests a decision aid tool that helps women with early-stage breast cancer choose between surgical options. It aims to support you in making a confident, informed decision about your care.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.